Post-Doctoral Scientist– Molecular Pharmacology
Eli Lilly and Company
August 30, 2026
Remote friendly (Indianapolis, IN)
United States
Clinical Research and Development
Responsibilities:
- Develop and validate assays to identify small molecule mitochondrial uncouplers.
- Characterize in vitro mitochondrial uncoupling activity across cell types, tissues, and disease-relevant systems.
- Design and execute small molecule screens to identify novel mitochondrial uncouplers; characterize mechanism of action, potency, selectivity, and safety margin.
- Work with and be mentored by experts in bioenergetics, molecular pharmacology, and metabolic disease biology.
- Identify areas of key need across clinical development and champion creative solutions; maintain external awareness and learning.
- Present findings at conferences and publish in high-quality peer-reviewed journals.
Basic Qualifications:
- Ph.D. in Molecular Biology, Biochemistry, Cell Biology, Pharmacology, or a related field.
- Authorized to work in the United States full-time; Lilly will not provide support or sponsor work authorization or visas.
Additional Skills/Preferences:
- Hands-on molecular biology experience, including CRISPR/Cas9 gene editing.
- Plate-based assay technologies (e.g., TR-FRET, BRET, AlphaLISA).
- Cellular target engagement assays (e.g., CETSA, NanoBRET) preferred.
- Cell-based imaging (high-content/high-throughput imaging, fluorescence microscopy, confocal) preferred.
- RT-PCR/qPCR proficiency.
- Proteomics and/or chemical biology approaches (e.g., mass spectrometry-based proteomics, activity-based protein profiling, chemical probe development) is a plus.
- Strong scientific communication and peer-reviewed publications.
Benefits:
- Full-time employees may be eligible for a company bonus; comprehensive benefits including 401(k), pension, vacation, medical/dental/vision/prescription, flexible benefits, life insurance, time off/leave of absence, and well-being benefits.
- Develop and validate assays to identify small molecule mitochondrial uncouplers.
- Characterize in vitro mitochondrial uncoupling activity across cell types, tissues, and disease-relevant systems.
- Design and execute small molecule screens to identify novel mitochondrial uncouplers; characterize mechanism of action, potency, selectivity, and safety margin.
- Work with and be mentored by experts in bioenergetics, molecular pharmacology, and metabolic disease biology.
- Identify areas of key need across clinical development and champion creative solutions; maintain external awareness and learning.
- Present findings at conferences and publish in high-quality peer-reviewed journals.
Basic Qualifications:
- Ph.D. in Molecular Biology, Biochemistry, Cell Biology, Pharmacology, or a related field.
- Authorized to work in the United States full-time; Lilly will not provide support or sponsor work authorization or visas.
Additional Skills/Preferences:
- Hands-on molecular biology experience, including CRISPR/Cas9 gene editing.
- Plate-based assay technologies (e.g., TR-FRET, BRET, AlphaLISA).
- Cellular target engagement assays (e.g., CETSA, NanoBRET) preferred.
- Cell-based imaging (high-content/high-throughput imaging, fluorescence microscopy, confocal) preferred.
- RT-PCR/qPCR proficiency.
- Proteomics and/or chemical biology approaches (e.g., mass spectrometry-based proteomics, activity-based protein profiling, chemical probe development) is a plus.
- Strong scientific communication and peer-reviewed publications.
Benefits:
- Full-time employees may be eligible for a company bonus; comprehensive benefits including 401(k), pension, vacation, medical/dental/vision/prescription, flexible benefits, life insurance, time off/leave of absence, and well-being benefits.